AMO's lens solution linked to AK

Article

A "strong association" has been discovered between use of AMO''s Complete MoisturePlus Multi-Purpose Solution and an increased risk of Acanthamoeba keratitis (AK).

A "strong association" has been discovered between use of AMO's Complete MoisturePlus Multi-Purpose Solution and an increased risk of Acanthamoeba keratitis (AK).

Earlier this year, AMO voluntarily recalled the product and since then an investigation of 30 AK cases and 39 matched controls wearing soft contact lenses, found that those with AK infection were significantly more likely to have reported use of the AMO solution than those without the infection. The researchers, from the University of Illinois, Chicago, USA, found that users of the solution have a greater than 16-fold risk of developing AK.

The researchers, however, also made it clear that 39% of AK cases reported no use of AMO Complete MoisturePlus Multi-Purpose solution. Furthermore, the investigation also offered some evidence that re-using contact lens solution, rubbing lenses during cleaning and showering with lenses on also increases the risk of infection.

The FDA is concerned that, despite the solution being withdrawn from the market, consumers might still be using it. The governing body therefore urges soft contact lens wearers to throw away any partially used bottles.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.